These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32017677)

  • 1. Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola.
    Legardy-Williams JK; Carter RJ; Goldstein ST; Jarrett OD; Szefer E; Fombah AE; Tinker SC; Samai M; Mahon BE
    Emerg Infect Dis; 2020 Mar; 26(3):541-548. PubMed ID: 32017677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing an Ebola Vaccine Study - Sierra Leone.
    Widdowson MA; Schrag SJ; Carter RJ; Carr W; Legardy-Williams J; Gibson L; Lisk DR; Jalloh MI; Bash-Taqi DA; Kargbo SA; Idriss A; Deen GF; Russell JB; McDonald W; Albert AP; Basket M; Callis A; Carter VM; Ogunsanya KR; Gee J; Pinner R; Mahon BE; Goldstein ST; Seward JF; Samai M; Schuchat A
    MMWR Suppl; 2016 Jul; 65(3):98-106. PubMed ID: 27387395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    Carter RJ; Idriss A; Widdowson MA; Samai M; Schrag SJ; Legardy-Williams JK; Estivariz CF; Callis A; Carr W; Webber W; Fischer ME; Hadler S; Sahr F; Thompson M; Greby SM; Edem-Hotah J; Momoh RM; McDonald W; Gee JM; Kallon AF; Spencer-Walters D; Bresee JS; Cohn A; Hersey S; Gibson L; Schuchat A; Seward JF
    J Infect Dis; 2018 May; 217(suppl_1):S16-S23. PubMed ID: 29788343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.
    Samai M; Seward JF; Goldstein ST; Mahon BE; Lisk DR; Widdowson MA; Jalloh MI; Schrag SJ; Idriss A; Carter RJ; Dawson P; Kargbo SAS; Leigh B; Bawoh M; Legardy-Williams J; Deen G; Carr W; Callis A; Lindblad R; Russell JBW; Petrie CR; Fombah AE; Kargbo B; McDonald W; Jarrett OD; Walker RE; Gargiullo P; Bash-Taqi D; Gibson L; Fofanah AB; Schuchat A;
    J Infect Dis; 2018 May; 217(suppl_1):S6-S15. PubMed ID: 29788345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
    Juan-Giner A; Tchaton M; Jemmy JP; Soumah A; Boum Y; Faga EM; Cisse M; Grais RF
    Vaccine; 2019 Nov; 37(48):7171-7177. PubMed ID: 30266489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein.
    Mahon BE; Simon J; Widdowson MA; Samai M; Rogier E; Legardy-Williams J; Liu K; Schiffer J; Lange J; DeByle C; Pinner R; Schuchat A; Slutsker L; Goldstein S
    J Infect Dis; 2021 Dec; 224(11):1907-1915. PubMed ID: 34013349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
    Choi EM; Lacarra B; Afolabi MO; Ale BM; Baiden F; Bétard C; Foster J; Hamzé B; Schwimmer C; Manno D; D'Ortenzio E; Ishola D; Keita CM; Keshinro B; Njie Y; van Dijck W; Gaddah A; Anumendem D; Lowe B; Vatrinet R; Lawal BJ; Otieno GT; Samai M; Deen GF; Swaray IB; Kamara AB; Kamara MM; Diagne MA; Kowuor D; McLean C; Leigh B; Beavogui AH; Leyssen M; Luhn K; Robinson C; Douoguih M; Greenwood B; Thiébaut R; Watson-Jones D;
    Lancet Glob Health; 2023 Nov; 11(11):e1743-e1752. PubMed ID: 37858585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
    Henao-Restrepo AM; Camacho A; Longini IM; Watson CH; Edmunds WJ; Egger M; Carroll MW; Dean NE; Diatta I; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Gsell PS; Hossmann S; Watle SV; Kondé MK; Kéïta S; Kone S; Kuisma E; Levine MM; Mandal S; Mauget T; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Røttingen JA; Kieny MP
    Lancet; 2017 Feb; 389(10068):505-518. PubMed ID: 28017403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
    Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
    J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014-2015 Ebola outbreak in Sierra Leone.
    Jalloh MF; Jalloh MB; Albert A; Wolff B; Callis A; Ramakrishnan A; Cramer E; Sengeh P; Pratt SA; Conteh L; Hajjeh R; Bunnell R; Redd JT; Ekström AM; Nordenstedt H
    Vaccine; 2019 Mar; 37(11):1495-1502. PubMed ID: 30755367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
    Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA;
    J Infect Dis; 2017 Jun; 215(12):1789-1798. PubMed ID: 28549145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
    Lai L; Davey R; Beck A; Xu Y; Suffredini AF; Palmore T; Kabbani S; Rogers S; Kobinger G; Alimonti J; Link CJ; Rubinson L; Ströher U; Wolcott M; Dorman W; Uyeki TM; Feldmann H; Lane HC; Mulligan MJ
    JAMA; 2015 Mar 24-31; 313(12):1249-55. PubMed ID: 25742465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    Schuchat A; Seward JF; Goldstein ST; Mahon BE
    J Infect Dis; 2018 May; 217(suppl_1):S1-S5. PubMed ID: 29788344
    [No Abstract]   [Full Text] [Related]  

  • 15. PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.
    Bolay FK; Grandits G; Lane HC; Kennedy SB; Johnson MP; Fallah MP; Wilson B; Njoh WS; McNay LA; Hensley LE; Higgs ES
    J Infect Dis; 2019 Apr; 219(10):1634-1641. PubMed ID: 30561672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    Conteh MA; Goldstein ST; Wurie HR; Gidudu J; Lisk DR; Carter RJ; Seward JF; Hampton LM; Wang D; Andersen LE; Arvay M; Schrag SJ; Dawson P; Fombah AE; Petrie CR; Feikin DR; Russell JBW; Lindblad R; Kargbo SAS; Samai M; Mahon BE
    J Infect Dis; 2018 May; 217(suppl_1):S33-S39. PubMed ID: 29788347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
    Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
    PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
    Badio M; Lhomme E; Kieh M; Beavogui AH; Kennedy SB; Doumbia S; Leigh B; Sow SO; Diallo A; Fusco D; Kirchoff M; Termote M; Vatrinet R; Wentworth D; Esperou H; Lane HC; Pierson J; Watson-Jones D; Roy C; D'Ortenzio E; Greenwood B; Chêne G; Richert L; Neaton JD; Yazdanpanah Y;
    Trials; 2021 Jan; 22(1):86. PubMed ID: 33485369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
    Boum Y; Juan-Giner A; Hitchings M; Soumah A; Strecker T; Sadjo M; Cuthbertson H; Hayes P; Tchaton M; Jemmy JP; Clarck C; King D; Faga EM; Becker S; Halis B; Gunnstein N; Carroll M; Røttingen JA; Kondé MK; Doumbia M; Henao-Restrepo AM; Kieny MP; Cisse M; Draguez B; Grais RF
    Vaccine; 2020 Jun; 38(31):4877-4884. PubMed ID: 32499066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.